生血宁片联合琥珀酸亚铁片治疗妊娠期缺铁性贫血患者的疗效及对铁代谢的影响

目的:探讨生血宁片联合琥珀酸亚铁片治疗妊娠期缺铁性贫血患者的疗效及对铁代谢的影响。方法:选取2015年2月-2017年2月我院收治的妊娠期缺铁性贫血患者200例为研究对象。将其以随机数字表法分成对照组(n=100)和研究组(n=100)。对照组予以口服琥珀酸亚铁片治疗,研究组则予以生血宁片联合琥珀酸亚铁片治疗,两组均连续治疗4周。分别比较两组临床疗效、治疗前后血液学指标、治疗前后铁代谢指标以及不良妊娠结局情况。结果:研究组治疗总有效率明显较对照组升高(P0.05)。治疗后两组患者血红蛋白(Hb)、红细胞(RBC)、平均红细胞体积(MCV)以及平均红细胞血红蛋白浓度(MCHC)水平均明显高于治疗前,且研究组高于对照组(P0.05)。治疗后两组患者血清铁、转铁蛋白饱和度(TSAT)水平均明显高于治疗前,且研究组又明显高于对照组(P0.05)。与对照组比较,研究组不良妊娠结局发生率降低(P0.05)。结论:生血宁片联合琥珀酸亚铁片治疗妊娠期缺铁性贫血患者的临床疗效显著,改善患者血液学指标以及铁代谢水平,降低不良妊娠结局发生风险,值得临床推广应用。

Curative Effect of Shengxuening Tablets Combined with Ferrous Succinate Tablets on Patients with Iron Deficiency Anemia During Pregnancy

ABSTRACT Objective: To investigate the curative effect of Shengxuening tablets combined with ferrous succinate tablets in the treatment of patients with iron deficiency anemia during pregnancy and its effect on iron metabolism. Methods: A total of 200 patients with iron deficiency anemia during pregnancy, who were treated in Shanghai First Maternity and Infant Hospital from February 2015 to February 2017, were selected and randomly divided into control group (n=100) and study group (n=100). The control group was treated with oral Ferrous Succinate Tablets, and the study group was treated with Shengxuening tablets combined with ferrous succinate tablets. The two groups were treated continuously for 4 weeks. The clinical efficacy, the hematology indexes before and after treatment, the iron metabolism indexes before and after treatment, and the adverse pregnancy outcome were compared between the two groups. Results: The total effective rate of treatment in the study group was significantly higher than that in the control group (P<0.05). After treatment, the levels of hemoglobin (Hb), red blood cell (RBC), mean corpuscular volume (MCV) and mean corpuscular hemoglobin concentration (MCHC) of the two groups were significantly higher than those before treatment, and the study group was higher than that in the control group (P<0.05). After treatment, the levels of serum iron and transferrin saturation (TSAT) in the two groups were significantly higher than those before treatment, and the study group was significantly higher than that of the control group (P<0.05). Compared with the con- trol group, the incidence of adverse pregnancy outcomes in the study group was reduced (P<0.05). Conclusion: Shengxuening tablets combined with Ferrous Succinate Tablets has a significant curative effect in the treatment of patients with iron deficiency anemia during pregnancy, and it can improve the hematological indexes and iron metabolism of patients and reduce the risk of adverse pregnancy out- comes, which is worthy of clinical application.